Business Context and Reporting Period
This Form 8-K is a current report filed by Leap Therapeutics, Inc. (not Cypherpunk Technologies Inc.) on April 1, 2021. The registrant is a Delaware corporation with its principal executive offices in Cambridge, MA, and its common stock trades on the Nasdaq Global Market under the symbol LPTX. The company is classified as an emerging growth company.
Key Financial Metrics
This filing is a current report regarding a specific corporate event and does not contain financial statements. Consequently, the filing text does not provide clear values for revenue, profit, cash flow, margins, debt, or liquidity.
Material Changes
The report discloses a material operational milestone under Item 8.01 (Other Events):
- On April 1, 2021, the Company announced the completion of enrollment for the first-line patient cohort in a clinical study.
- The study evaluates DKN-01 in combination with Tislelizumab for the treatment of gastric or gastroesophageal junction cancer.
Guidance, Outlook, and Risks
The filing incorporates a press release (Exhibit 99.1) detailing the clinical milestone but does not provide specific financial guidance, updated outlook figures, or new risk factors within the body of this report. The Company explicitly states that information on its website referenced in the press release is not incorporated by reference.
Investor Verification Checklist
- Verify the full text of the press release filed as Exhibit 99.1 for detailed clinical trial data.
- Confirm the company name is Leap Therapeutics, Inc. (LPTX), as the request metadata contained a discrepancy.
- Review the Company's most recent 10-K or 10-Q for financial metrics, as this 8-K contains no financial data.
- Monitor future filings for data readouts from the DKN-01 and Tislelizumab combination study.